Global Bioengineered Protein Drugs Market by Type (Recombinant protein drugs, Peptide hormones, Vaccines, Therapeutic enzymes, Monoclonal antibodies, Cytokines, Replacement proteins, Peptide antibiotics, Blood products), By Application (Fractionation, Bioreactors and microbial cell fermentation, Genetic engineering, Genetically modified organisms, Pharming, Bioengineered protein drugs produced by transgenic microorganisms, plants and animals, Cell culture, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Bioengineered Protein Drugs Market research report which is segmented by Types (Recombinant protein drugs, Peptide hormones, Vaccines, Therapeutic enzymes, Monoclonal antibodies, Cytokines, Replacement proteins, Peptide antibiotics, Blood products), By Applications (Fractionation, Bioreactors and microbial cell fermentation, Genetic engineering, Genetically modified organisms, Pharming, Bioengineered protein drugs produced by transgenic microorganisms, plants and animals, Cell culture, Others), By Players/Companies Abbot, Amgen, Baxter, Bayer, Eli Lilly, GlaxoSmithKline, Fresenius Kabi, Hoffman-la-Roche, Johnson & Johnson, Merck”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Bioengineered Protein Drugs Market Research Report |
| By Type | Recombinant protein drugs, Peptide hormones, Vaccines, Therapeutic enzymes, Monoclonal antibodies, Cytokines, Replacement proteins, Peptide antibiotics, Blood products |
| By Application | Fractionation, Bioreactors and microbial cell fermentation, Genetic engineering, Genetically modified organisms, Pharming, Bioengineered protein drugs produced by transgenic microorganisms, plants and animals, Cell culture, Others |
| By Companies | Abbot, Amgen, Baxter, Bayer, Eli Lilly, GlaxoSmithKline, Fresenius Kabi, Hoffman-la-Roche, Johnson & Johnson, Merck |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 248 |
| Number of Tables & Figures | 174 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Bioengineered Protein Drugs Market Report Segments:
The market is segmented by Type Recombinant protein drugs, Peptide hormones, Vaccines, Therapeutic enzymes, Monoclonal antibodies, Cytokines, Replacement proteins, Peptide antibiotics, Blood products and By Application Fractionation, Bioreactors and microbial cell fermentation, Genetic engineering, Genetically modified organisms, Pharming, Bioengineered protein drugs produced by transgenic microorganisms, plants and animals, Cell culture, Others.
Some of the companies that are profiled in this report are:
- Abbot
- Amgen
- Baxter
- Bayer
- Eli Lilly
- GlaxoSmithKline
- Fresenius Kabi
- Hoffman-la-Roche
- Johnson & Johnson
- Merck
Bioengineered Protein Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Bioengineered Protein Drugs Market
Overview of the regional outlook of the Bioengineered Protein Drugs Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Bioengineered Protein Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Bioengineered Protein Drugs Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. Recombinant protein drugs
2. Peptide hormones
3. Vaccines
4. Therapeutic enzymes
5. Monoclonal antibodies
6. Cytokines
7. Replacement proteins
8. Peptide antibiotics
9. Blood products
7. By Application:1. Fractionation
2. Bioreactors and microbial cell fermentation
3. Genetic engineering
4. Genetically modified organisms
5. Pharming
6. Bioengineered protein drugs produced by transgenic microorganisms, plants and animals
7. Cell culture
8. Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bioengineered Protein Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Bioengineered Protein Drugs Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bioengineered Protein Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bioengineered Protein Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bioengineered Protein Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bioengineered Protein Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bioengineered Protein Drugs Market Size & Forecast, 2018-2028
4.5.1 Bioengineered Protein Drugs Market Size and Y-o-Y Growth
4.5.2 Bioengineered Protein Drugs Market Absolute $ Opportunity
Chapter 5 Global Bioengineered Protein Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bioengineered Protein Drugs Market Size Forecast by Type
5.2.1 Recombinant protein drugs
5.2.2 Peptide hormones
5.2.3 Vaccines
5.2.4 Therapeutic enzymes
5.2.5 Monoclonal antibodies
5.2.6 Cytokines
5.2.7 Replacement proteins
5.2.8 Peptide antibiotics
5.2.9 Blood products
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bioengineered Protein Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bioengineered Protein Drugs Market Size Forecast by Applications
6.2.1 Fractionation
6.2.2 Bioreactors and microbial cell fermentation
6.2.3 Genetic engineering
6.2.4 Genetically modified organisms
6.2.5 Pharming
6.2.6 Bioengineered protein drugs produced by transgenic microorganisms
6.2.7 plants and animals
6.2.8 Cell culture
6.2.9 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bioengineered Protein Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bioengineered Protein Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bioengineered Protein Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Bioengineered Protein Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bioengineered Protein Drugs Market Size Forecast by Type
9.6.1 Recombinant protein drugs
9.6.2 Peptide hormones
9.6.3 Vaccines
9.6.4 Therapeutic enzymes
9.6.5 Monoclonal antibodies
9.6.6 Cytokines
9.6.7 Replacement proteins
9.6.8 Peptide antibiotics
9.6.9 Blood products
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bioengineered Protein Drugs Market Size Forecast by Applications
9.10.1 Fractionation
9.10.2 Bioreactors and microbial cell fermentation
9.10.3 Genetic engineering
9.10.4 Genetically modified organisms
9.10.5 Pharming
9.10.6 Bioengineered protein drugs produced by transgenic microorganisms
9.10.7 plants and animals
9.10.8 Cell culture
9.10.9 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bioengineered Protein Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Bioengineered Protein Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bioengineered Protein Drugs Market Size Forecast by Type
10.6.1 Recombinant protein drugs
10.6.2 Peptide hormones
10.6.3 Vaccines
10.6.4 Therapeutic enzymes
10.6.5 Monoclonal antibodies
10.6.6 Cytokines
10.6.7 Replacement proteins
10.6.8 Peptide antibiotics
10.6.9 Blood products
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bioengineered Protein Drugs Market Size Forecast by Applications
10.10.1 Fractionation
10.10.2 Bioreactors and microbial cell fermentation
10.10.3 Genetic engineering
10.10.4 Genetically modified organisms
10.10.5 Pharming
10.10.6 Bioengineered protein drugs produced by transgenic microorganisms
10.10.7 plants and animals
10.10.8 Cell culture
10.10.9 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bioengineered Protein Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bioengineered Protein Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bioengineered Protein Drugs Market Size Forecast by Type
11.6.1 Recombinant protein drugs
11.6.2 Peptide hormones
11.6.3 Vaccines
11.6.4 Therapeutic enzymes
11.6.5 Monoclonal antibodies
11.6.6 Cytokines
11.6.7 Replacement proteins
11.6.8 Peptide antibiotics
11.6.9 Blood products
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bioengineered Protein Drugs Market Size Forecast by Applications
11.10.1 Fractionation
11.10.2 Bioreactors and microbial cell fermentation
11.10.3 Genetic engineering
11.10.4 Genetically modified organisms
11.10.5 Pharming
11.10.6 Bioengineered protein drugs produced by transgenic microorganisms
11.10.7 plants and animals
11.10.8 Cell culture
11.10.9 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bioengineered Protein Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Bioengineered Protein Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bioengineered Protein Drugs Market Size Forecast by Type
12.6.1 Recombinant protein drugs
12.6.2 Peptide hormones
12.6.3 Vaccines
12.6.4 Therapeutic enzymes
12.6.5 Monoclonal antibodies
12.6.6 Cytokines
12.6.7 Replacement proteins
12.6.8 Peptide antibiotics
12.6.9 Blood products
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bioengineered Protein Drugs Market Size Forecast by Applications
12.10.1 Fractionation
12.10.2 Bioreactors and microbial cell fermentation
12.10.3 Genetic engineering
12.10.4 Genetically modified organisms
12.10.5 Pharming
12.10.6 Bioengineered protein drugs produced by transgenic microorganisms
12.10.7 plants and animals
12.10.8 Cell culture
12.10.9 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bioengineered Protein Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bioengineered Protein Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bioengineered Protein Drugs Market Size Forecast by Type
13.6.1 Recombinant protein drugs
13.6.2 Peptide hormones
13.6.3 Vaccines
13.6.4 Therapeutic enzymes
13.6.5 Monoclonal antibodies
13.6.6 Cytokines
13.6.7 Replacement proteins
13.6.8 Peptide antibiotics
13.6.9 Blood products
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bioengineered Protein Drugs Market Size Forecast by Applications
13.10.1 Fractionation
13.10.2 Bioreactors and microbial cell fermentation
13.10.3 Genetic engineering
13.10.4 Genetically modified organisms
13.10.5 Pharming
13.10.6 Bioengineered protein drugs produced by transgenic microorganisms
13.10.7 plants and animals
13.10.8 Cell culture
13.10.9 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bioengineered Protein Drugs Market: Competitive Dashboard
14.2 Global Bioengineered Protein Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbot
14.3.2 Amgen
14.3.3 Baxter
14.3.4 Bayer
14.3.5 Eli Lilly
14.3.6 GlaxoSmithKline
14.3.7 Fresenius Kabi
14.3.8 Hoffman-la-Roche
14.3.9 Johnson & Johnson
14.3.10 Merck
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bioengineered Protein Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bioengineered Protein Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bioengineered Protein Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bioengineered Protein Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bioengineered Protein Drugs Market Size & Forecast, 2018-2028
4.5.1 Bioengineered Protein Drugs Market Size and Y-o-Y Growth
4.5.2 Bioengineered Protein Drugs Market Absolute $ Opportunity
Chapter 5 Global Bioengineered Protein Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bioengineered Protein Drugs Market Size Forecast by Type
5.2.1 Recombinant protein drugs
5.2.2 Peptide hormones
5.2.3 Vaccines
5.2.4 Therapeutic enzymes
5.2.5 Monoclonal antibodies
5.2.6 Cytokines
5.2.7 Replacement proteins
5.2.8 Peptide antibiotics
5.2.9 Blood products
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bioengineered Protein Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bioengineered Protein Drugs Market Size Forecast by Applications
6.2.1 Fractionation
6.2.2 Bioreactors and microbial cell fermentation
6.2.3 Genetic engineering
6.2.4 Genetically modified organisms
6.2.5 Pharming
6.2.6 Bioengineered protein drugs produced by transgenic microorganisms
6.2.7 plants and animals
6.2.8 Cell culture
6.2.9 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bioengineered Protein Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bioengineered Protein Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bioengineered Protein Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Bioengineered Protein Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bioengineered Protein Drugs Market Size Forecast by Type
9.6.1 Recombinant protein drugs
9.6.2 Peptide hormones
9.6.3 Vaccines
9.6.4 Therapeutic enzymes
9.6.5 Monoclonal antibodies
9.6.6 Cytokines
9.6.7 Replacement proteins
9.6.8 Peptide antibiotics
9.6.9 Blood products
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bioengineered Protein Drugs Market Size Forecast by Applications
9.10.1 Fractionation
9.10.2 Bioreactors and microbial cell fermentation
9.10.3 Genetic engineering
9.10.4 Genetically modified organisms
9.10.5 Pharming
9.10.6 Bioengineered protein drugs produced by transgenic microorganisms
9.10.7 plants and animals
9.10.8 Cell culture
9.10.9 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bioengineered Protein Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Bioengineered Protein Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bioengineered Protein Drugs Market Size Forecast by Type
10.6.1 Recombinant protein drugs
10.6.2 Peptide hormones
10.6.3 Vaccines
10.6.4 Therapeutic enzymes
10.6.5 Monoclonal antibodies
10.6.6 Cytokines
10.6.7 Replacement proteins
10.6.8 Peptide antibiotics
10.6.9 Blood products
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bioengineered Protein Drugs Market Size Forecast by Applications
10.10.1 Fractionation
10.10.2 Bioreactors and microbial cell fermentation
10.10.3 Genetic engineering
10.10.4 Genetically modified organisms
10.10.5 Pharming
10.10.6 Bioengineered protein drugs produced by transgenic microorganisms
10.10.7 plants and animals
10.10.8 Cell culture
10.10.9 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bioengineered Protein Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bioengineered Protein Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bioengineered Protein Drugs Market Size Forecast by Type
11.6.1 Recombinant protein drugs
11.6.2 Peptide hormones
11.6.3 Vaccines
11.6.4 Therapeutic enzymes
11.6.5 Monoclonal antibodies
11.6.6 Cytokines
11.6.7 Replacement proteins
11.6.8 Peptide antibiotics
11.6.9 Blood products
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bioengineered Protein Drugs Market Size Forecast by Applications
11.10.1 Fractionation
11.10.2 Bioreactors and microbial cell fermentation
11.10.3 Genetic engineering
11.10.4 Genetically modified organisms
11.10.5 Pharming
11.10.6 Bioengineered protein drugs produced by transgenic microorganisms
11.10.7 plants and animals
11.10.8 Cell culture
11.10.9 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bioengineered Protein Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Bioengineered Protein Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bioengineered Protein Drugs Market Size Forecast by Type
12.6.1 Recombinant protein drugs
12.6.2 Peptide hormones
12.6.3 Vaccines
12.6.4 Therapeutic enzymes
12.6.5 Monoclonal antibodies
12.6.6 Cytokines
12.6.7 Replacement proteins
12.6.8 Peptide antibiotics
12.6.9 Blood products
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bioengineered Protein Drugs Market Size Forecast by Applications
12.10.1 Fractionation
12.10.2 Bioreactors and microbial cell fermentation
12.10.3 Genetic engineering
12.10.4 Genetically modified organisms
12.10.5 Pharming
12.10.6 Bioengineered protein drugs produced by transgenic microorganisms
12.10.7 plants and animals
12.10.8 Cell culture
12.10.9 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bioengineered Protein Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bioengineered Protein Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bioengineered Protein Drugs Market Size Forecast by Type
13.6.1 Recombinant protein drugs
13.6.2 Peptide hormones
13.6.3 Vaccines
13.6.4 Therapeutic enzymes
13.6.5 Monoclonal antibodies
13.6.6 Cytokines
13.6.7 Replacement proteins
13.6.8 Peptide antibiotics
13.6.9 Blood products
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bioengineered Protein Drugs Market Size Forecast by Applications
13.10.1 Fractionation
13.10.2 Bioreactors and microbial cell fermentation
13.10.3 Genetic engineering
13.10.4 Genetically modified organisms
13.10.5 Pharming
13.10.6 Bioengineered protein drugs produced by transgenic microorganisms
13.10.7 plants and animals
13.10.8 Cell culture
13.10.9 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bioengineered Protein Drugs Market: Competitive Dashboard
14.2 Global Bioengineered Protein Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbot
14.3.2 Amgen
14.3.3 Baxter
14.3.4 Bayer
14.3.5 Eli Lilly
14.3.6 GlaxoSmithKline
14.3.7 Fresenius Kabi
14.3.8 Hoffman-la-Roche
14.3.9 Johnson & Johnson
14.3.10 Merck
Segments Covered in the Report
The global Bioengineered Protein Drugs market has been segmented based on
By Types
The global Bioengineered Protein Drugs market has been segmented based on
By Types
- Recombinant protein drugs
- Peptide hormones
- Vaccines
- Therapeutic enzymes
- Monoclonal antibodies
- Cytokines
- Replacement proteins
- Peptide antibiotics
- Blood products
- Fractionation
- Bioreactors and microbial cell fermentation
- Genetic engineering
- Genetically modified organisms
- Pharming
- Bioengineered protein drugs produced by transgenic microorganisms, plants and animals
- Cell culture
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Abbot
- Amgen
- Baxter
- Bayer
- Eli Lilly
- GlaxoSmithKline
- Fresenius Kabi
- Hoffman-la-Roche
- Johnson & Johnson
- Merck
Our Clients
Related Reports
Some other reports from this category!
